{"groups":[{"description":"Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.\n\nCarfilzomib: Given IV\n\nDexamethasone: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"FG000","title":"Arm I (Dexamethasone, Low-dose Carfilzomib)"},{"description":"Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nCarfilzomib: Given IV\n\nDexamethasone: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"FG001","title":"Arm II (Dexamethasone, High-dose Carfilzomib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"No measurable disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Incomplete/discontinued prior therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"11"}],"type":"Baseline lab missing/incomplete/untimely"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"71"}],"type":"STARTED"},{"achievements":[{"comment":"Following disease progression on Arm I. Note: these patients are also counted in 'Completed'.","groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"0"}],"type":"Crossover to Arm II"},{"achievements":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"57"}],"comment":"Completed implies patients were eligible for study treatment and analyzable for study endpoints.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"14"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}